Theriva Enterprise Value Over E B I T D A from 2010 to 2024
| TOVX Stock | USD 1.28 0.02 1.59% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 0.71018435 | Current Value 0.75 | Quarterly Volatility 52.33322324 |
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.17. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
Theriva | Enterprise Value Over E B I T D A |
Latest Theriva Biologics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Theriva Biologics over the last few years. It is Theriva Biologics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Theriva Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (51.16) | |
| Coefficient Of Variation | (102.29) | |
| Mean Deviation | 44.49 | |
| Median | (45.45) | |
| Standard Deviation | 52.33 | |
| Sample Variance | 2,739 | |
| Range | 152 | |
| R-Value | 0.63 | |
| Mean Square Error | 1,793 | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 7.33 | |
| Total Sum of Squares | 38,343 |
Theriva Enterprise Value Over E B I T D A History
About Theriva Biologics Financial Statements
Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 0.71 | 0.75 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.